Metylfenidat Teva

Methylphenidate, the active ingredient in Metylfenidat Teva, is a central nervous system stimulant presented as an oral dosage form for oral use. It is prescribed to manage attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults, helping improve focus and reduce excessive daytime sleepiness.

GNH USA supplies Metylfenidat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The company ensures product integrity through stringent quality controls and regulatory compliance.

Methylphenidate is a central nervous system stimulant used in conditions that affect attention and wakefulness.

ADHD: improves attention, reduces hyperactivity and impulsivity Narcolepsy: decreases excessive daytime sleepiness and enhances wakefulness

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep - Decreased appetite: reduced hunger leading to weight loss - Headache: mild to moderate cranial pain - Stomach pain: abdominal discomfort or nausea

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmias - Psychosis: hallucinations or delusional thinking - Severe allergic reaction: rash, swelling, or anaphylaxis - Priapism: prolonged, painful erection requiring urgent care

When prescribing methylphenidate, clinicians should consider several safety factors.

Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy Psychiatric monitoring: watch for emergence of psychosis or severe mood changes Substance abuse risk: assess history of drug misuse before use Use in children: monitor growth and weight regularly during treatment Concomitant MAO inhibitors: avoid use within 14 days of MAOI therapy Store at room temperature: keep in original container, protect from moisture and light

Methylphenidate can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis when combined - Antihypertensive agents (alpha‑blockers): may reduce blood pressure control - Tricyclic antidepressants: increased risk of cardiovascular side effects

Moderate Interactions (Monitor Closely):\n- SSRIs: may increase serotonin levels and risk of serotonin syndrome - Antacids: may affect drug absorption and bioavailability